on this page
Please note: You’ll get an immediate assessment when you request PBS authorities online.
Patient eligibility
The Pharmaceutical Benefits Scheme (PBS) subsidises treatment with larotrectinib under the National Health Act 1953, section 85 for patients with solid tumours with confirmed NTRK gene fusion.
Patients must be eligible for the PBS and meet the relevant restriction criteria.
The Schedule of Pharmaceutical Benefits on the PBS website outlines the restrictions for prescribing larotrectinib.
Authority applications
Applying for initial treatment
Applications for initial authority approval to prescribe PBS-subsidised larotrectinib to treat solid tumours with confirmed NTRK gene fusion can be made either in:
- real time using the Online PBS Authorities system
- writing and use HPOS Form upload
- writing and mail to PBS Complex Drugs Programs.
All written applications must include:
- details of the proposed prescription or prescriptions
- the completed solid tumours with confirmed NTRK gene fusion - larotrectinib - initial authority application form
- relevant attachments.
Applying for continuing treatment
Applications for continuing authority approval to prescribe PBS-subsidised larotrectinib to treat solid tumours with confirmed NTRK gene fusion can be made either:
- in real time using the Online PBS Authorities system
- by calling the PBS Complex Drugs Programs enquiry line.
More information
Call the PBS Complex Drugs Programs enquiry line for more information.